Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines.

[1][2][3][4][5][6][7][8] Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions.

[2][10][11][9] These include benzofurans like 5-MAPB, 5-MBPB, and BK-5-MAPB,[12][13][14][15] benzothiophenes like 5-MAPBT,[16][15] α-alkyltryptamines like BK-NM-AMT,[17] indolizines like 2ZEDMA, 1ZP2MA, and Z2MAP1O,[18][19] 2-aminoindanes like "BFAI",[20] and non-racemic mixtures of enantiomers.

[1] Phase 1 and 2 clinical trials of Tactogen's drug candidates in healthy volunteers and people with post-traumatic stress disorder (PTSD) are said to be in the planning stages as of February 2024.

[7][25][23] Following the Food and Drug Administration (FDA)'s rejection of Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD), Tactogen said in late 2024 that it is seriously considering prioritizing its novel compounds over its MDMA/citalopram product.